J. B. Chemicals & Pharmaceuticals Ltd. www.jbcpl.com © Copyright 2005 J. B. Chemicals Pharma Ltd. Electronic Submissions – eCTD Advantages Dr Milind Joshi.

Slides:



Advertisements
Similar presentations
© 2011 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International.
Advertisements

1 Future strategy for e-submission as seen by industry Dr Michael Colmorgen, IFAH-Europe 2nd Veterinary Workshop on E-submission 4 Dec 2009, EMEA, London.
ECTD Submissions: Guide to BookMarking and Hypertext Linking (Last Updated: March-09) Prepared By:
Infrastructures For Information Inc. The Collaborative XML Content Company Content Company.
Dr. Raghuveer Pharma Consultants D R P C Quality. Perfection. Confidentiality. D R P C Quality. Perfection. Confidentiality. 1.
GMP Document and Record Retention
eCTD – A TOOL to QUICK /RELIABLE REGULATORY SUBMISSION
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Workshop on e-submissions in the veterinary sector Neil Paterson, David Lewsey and Alex Tait Veterinary Medicines Directorate, UK A proposal for electronic.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
Office of Food Additive Safety Information for Industry: Steps to Implementation of Electronic Submissions.
©2014 Factorytalk Co., Ltd. Proprietary and Confidential eCTD Specification 17 July 2014.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Document Management Systems For Human Resource Department Infocrew Solutions Pvt.Ltd.
Instructions and forms
Structure of Dossier of Medicinal Product- Q part
EFPIA EFPIA IT Proposals ppt Slide 1 EFPIA Proposals for IT Support to the European Regulatory Procedures Mr S. Hasler EFPIA PAT Regulation 2000.
1 Building an eSubmissions System Ed Tripp Program Director Abbott Laboratories.
ICH Public Meeting January 21, Fishers Lane, Room 1066 FDA PERSPECTIVE IMPLEMENTATION STATUS OF THE CTD Justina A. Molzon, M.S. Pharm., J.D.
4 OFFICE WEEKLY MEETING Why 4 Office DMS?. Challenge Companies today are overwhelmed with information that comes to them on many formats: , electronic.
SWIS Digital Inspections Project (SWIS DIP) Chris Allen, Information Management Branch California Integrated Waste Management Board November 5, 2008 The.
Regulatory Affairs Domain
Justina A. Molzon, MS Pharm, JD
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
DEPARTMENT OF HEALTH Medicines Regulatory Affairs
Best Archival Practice in the Regulation of Medicines: Work on the Guidelines for Agencies for Medicinal Products Ph.D. Arian Rajh Agency for Medicinal.
Quality by Design & Question-Based Review: Observations by the Generic Pharmaceutical Industry Advisory Committee for Pharmaceutical Science October 5,
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Large Multicenter Clinical Trials George.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
SWIS Digital Inspections Project Chris Allen, Information Management Branch California Integrated Waste Management Board August 22, 2008.
ICH and CTD November 19, 2002 Kimberly Stranick, Ph.D. Worldwide Regulatory Affairs The Common Technical Document.
CTD Dossier Preparation K. Srikantha Reddy Sr
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Labeling and Electronic Initiatives Rachel E. Behrman M.D., M.P.H. Deputy Director, Office of Medical Policy CDER FDA Science Board, April 15, 2005.
FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,
The world leader in serving science Validation and Qualification Overview Mike Garry Software Product Manager Spectroscopy Software Platform Team.
Results of IFAH Survey on readiness of Industry for e- Submissions 7 May 2009.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
SAPRAA 5 Sept 2008 eCTD An overview of the full day presentation by Dr Olaf Schoepke at the SAAPI conference in July 2008.
The assessment process in “stringent” authorities Regine Lehnert Training workshop: Regulatory requirements for registration of Artemisinin based combined.
1 COMMON TECHNICAL DOCUMENT / ORIGIN OF CTD… ICH EWG CTD WAS OFFICIALLY SIGNED OFF IN NOVEMBER 2000, AT 5 TH ICH CONFERENCE; SAN DIEGO,CALIFORNIA.
DMF Procedures and Communication between API, FFP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern Workshop 2 - Paragraph 13 TPA 2nd Follow-up Information.
Abstract References Why CTD ? CTD is an ICH standard that FDA adopted in a consensus process, as a member of ICH, together with other member regions, Europe.
An Overview of eCTD for CMC Specialists Dr Martin Moxham June 2010 iRegulatory Ltd, 1 Viewpoint Office Village, Babbage Road, Stevenage, SG1 2EQ, United.
Regulated Product Submission Eileen M. Girten, MS i3 Statprobe 1DIA Education SIAC.
Experience from a Generic Dossier Dr. Roger Bolten, 16 th March 2011.
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Regulatory Intelligence for the Emerging Markets Lisa Rysso-DeMaggio President, RAQUELIAN Consulting DIA Regulatory Intelligence Working Group, 10 Sep.
FDA 21 CFR Part 11 Compliance
- A “Portable” Implementation
PROJECT COMMUNICATION PROCEDURE AND DOCUMENT MANAGEMENT
CTD Content Management
LNH Pharma A Trusted Partner.
Nonclinical Information in the Common Technical Document: Opportunities for Content Reuse Peggy Zorn, MPI Research Susan Mattano, Pfizer, Inc.
Handling ongoing variations concerning same document
Welcome to: eCTD Hands-on Workshop
JSS College of Pharmacy Ooty, Tamil Nadu Sunday, April 24th , 2016
Labeling and Electronic Initiatives
11/18/2018 What is NDS? A Management Information System (MIS) for national and international drug control Automates range of day-to-day drug control.
EU SUBMISSION BY Haripriya & Revathy.
STF-Study tagging file
Business Cases and Advantages of eCTD v4.0
Fundamentals of Electronic Submissions and eCTD
Business View on eCTD v4.0 Advantages and challenges when considering implementation to overcome constrains of the current eCTD specification.
Say it in XBRL & the World will Listen
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Presentation transcript:

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. Electronic Submissions – eCTD Advantages Dr Milind Joshi President – Global Regulatory Management

Change is the only universal constant J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pvt. Ltd.

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd.  Every regulatory submission is data submission  Dossier structure is complicated  Variety  Quantity  Lack of clarity  Confusing and cumbersome review process  Voluminous data  Diverse data  Multiple expertise needed for complete review  Evolution Data Management and Review

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. CTD – Structure  Module 1 is not part of CTD  Contains regional information and prescribing information

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. eCTD Modules  Module 1 ( Region specific Information) Environmental Assessment, declarations and forms  Module 2 ( Summaries) -2.3.Quality overall Summary -and Summary of Modules 4 and 5 (e.g. BE Tables)  Module 3 -Drug substance -Drug Product -Appendices -Batch information

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. eCTD Modules ( contd..) Module 4  Non-Clinical study report and related data Module 5  Clinical study reports, CRFs, & In –vitro comparative dissolution data, etc.  Bioequivalence studies in ANDA submission  STF (study tagging files) submission  STFs required by Unites states, optional in Europe & Japan

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. Data / Dossier Structure Old timesCTDeCTD Administrative / Regional Module 1 Administrative / Regional Module 1 Chemistry Manufacture Control Quality Module 3 Quality Module 3 Non-Clinical / Clinical / BE Non-Clinical Module 4 Non-Clinical Module 4 Clinical/BE Module 5 Clinical/BE Module 5 Summary / Synopsis Summary Module 2 Summary Module 2 No set structureSet structure but without granularity Very definite structure with detailed granularity Xml backbone

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. CTD – Common Technical Document  Technical Document – data necessary for proving safety, efficacy and quality of a drug product  CTD – initiative to formalise the technical data  Wide acceptance of the format  Led to discipline in catagorising and presentation of data  Facilitated the review procedure of the huge data  Still many copies of data needed, repeat efforts and confusions unavoidable  Updates in data and version control was cumbersome

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. eCTD – Electronic CTD  The format for data compilation remains same  Presentation is electronic and not paper  Undergoing evolution in eCTD for last few years  Initiative for better metadata and data management  Initiative for searchability and faster review  Initiative for better version control and change management

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. eCTD  Data that used to be submitted on paper, is submitted on a CD / uploaded on a server  Like guidance for how paper should be, there is guidance for how the files should be  Specific software / application for formation of eCTD  Choice of software / application  Knowledge of not just regulatory requirements but also IT aspects  Not just QbD for product but also Accuracy by Design for data compilation

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. eCTD Emergence Paper submission  NeeS  eCTD Late 80’s  2008 for complete transfer at USFDA  Disadvantages of Paper Submission  Exponentially increased number of dossiers any MoH / Regulatory Authority receives in recent times  Need for faster and more efficient review  Need for better searchability, user friendliness and harmonisation

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. Disadvantages of Paper Submissions  Voluminous data – difficult to handle  Person dependant for storage and retrieval  Not searchable  Not reusable  Can be lost  Can not be secured  Updates in data is difficult to track  Difficult version control  Eco-friendly (One copy of CTD dossier = 1 tree)

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. eCTD  Most far-reaching change in regulatory data management  Needs upgradation and learning at different levels in a company  Constantly changing / evolving hence needs constant training  Management needs to approve the high end software facility or out-sourcing fees  Regulatory officers / executive should learn the detailed requirements – not just pharma-technical but also IT-technical

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. CTD & eCTD  Scientific approach  CTD mandatory in the ASEAN, USA, EU & Japan  eCTD ‘must’ for USFDA  Common dossier for all countries with different Module 1 with regional information  Infrastructure created at USFDA for eCTD  Document management capability at USFDA  Version control at USFDA & at user’s end  Paperless  Reduced review time

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. Submission Review Tools  Tools provided on an as-is basis with no support from FDA  Support from 3 rd party tools developers to submit and validation of submission prior to FDA submissions.  Adherence to the eCTD specification is critical  Validation of the submission very crucial

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. Review Process

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. eCTD Requirements  File formats – pdf, xpt, doc, jpg  Doc, xpt and jpg files only allowed in certain modules  Software to have maximum granularity  All pdf files should be searchable / OCRed, vertically oriented  Norms for file naming  Norms for title  Norms for how to write title and file name  Other norms of margins, fonts etc – same as paper compilation  Thorough bookmarking and hyperlinking  No repeatation of data within metadata

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. Requirements – Successful eCTD Application  eCTD software ( Good support from vendor )  Quality of HR  IT infrastructure  Understanding of the software & regulatory guidance  Training & updating with current guidance

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. eCTD Advantages  Handling of smaller physical form of data compilation like CD  No copies (coloured bound dossiers, field copies etc)  Easily reviewable  Searchable  Life-cycle management of dossiers  Easy updates  Version control  No repetition of data  Maneuverability and easy cross-linking within metadata  Maneuverability and easy cross-linking within data

J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. Thank you !!!